Control CD19-CAR T cells and mock T cells did not exhibit any therapeutic effect, while GSK-primed CD19-CAR T cells strongly inhibited leukemia progression and extended animal survival (Fig. 7h–j). The gene discussed is CD19; the disease is leukemia.